Cardiol Therapeutics Inc. (NASDAQ : CRDL) Stock

Cardiol Therapeutics Inc. is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAVERIC study, published in the Journal of the American Heart Association, and the ongoing pivotal Phase III MAVERIC trial. The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study, published in ESC Heart Failure, which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The company is advancing its lead product candidate, CardiolRx™, an oral small-molecule targeting the NLRP3 inflammasome pathway to treat cardiac inflammation without the risk of immune suppression.

Cardiol's most advanced program is the pivotal Phase III MAVERIC trial evaluating CardiolRx™ in patients with recurrent pericarditis for the reduction is risk of recurrence. Following positive Phase II MAVERIC results — now published in the Journal of the American Heart Association in July 2026 — the company is now running the pivotal Phase III MAVERIC trial, which had surpassed 75% enrollment by spring 2026, with 100% enrollment targeted in Q3 2026 and topline results expected in Q1 2027. In parallel, Cardiol's Phase II ARCHER trial in acute myocarditis patients delivered significant left-ventricular mass reduction (comparable to major cardiometabolic drugs) and structural heart improvements that translate to heart failure; results were published in ESC Heart Failure.

Given the growing interest in targeting inflammation in cardiovascular diseases, Cardiol is capitalizing on the therapeutic benefits that may arise from its drug formulation. As the company approaches full enrollment and anticipates topline Phase III data, it remains focused on establishing CardiolRx™ as a potential new standard of care for patients with recurrent pericarditis and other inflammatory heart conditions.

In addition to its flagship product CardiolRx™, Cardiol Therapeutics is also expanding into heart failure—a market exceeding $30 billion in U.S. healthcare costs annually—with CRD-38. IND-enabling studies are underway to transition this subcutaneously administered drug, also targeting inflammation, into Phase I human trials. CRD-38 has demonstrated promising results in pre-clinical studies, showcasing its ability to improve heart function and potentially improve patient outcomes and reduce hospitalizations in patients with heart failure.

Investors are keeping a close watch on Cardiol's clinical progress and market developments, as achieving key milestones may significantly enhance the company's valuation and position in the competitive biotech landscape. Overall, Cardiol Therapeutics represents an intriguing opportunity within the evolving realm of cardiovascular treatments.